INTERCURE LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,266 ILa | +4.89% |
|
+26.61% | +173.38% |
| May. 01 | InterCure Ltd. Provides Revenue Guidance for the Full Year 2024 | CI |
| May. 01 | InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 417.5 | 404.1 | 440.5 | 932.3 | 550.5 | 211 |
| Enterprise Value (EV) 1 | 426.6 | 393.6 | 407.6 | 844.6 | 572.9 | 300.8 |
| P/E ratio | -31.6 x | -124 x | -11.2 x | 207 x | 12.2 x | -3.41 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 45,271,664 x | 6,773,655 x | 4,243,845 x | 1,416,365 x | 593,574 x |
| EV / Revenue | - | 44,099,358 x | 6,268,065 x | 3,844,919 x | 1,473,908 x | 845,888 x |
| EV / EBITDA | -42.1 x | -4.96 x | 286 x | 23.8 x | 11.9 x | -10.8 x |
| EV / FCF | 161 x | -18.4 x | -33 x | 116 x | -12.3 x | -2.64 x |
| FCF Yield | 0.62% | -5.44% | -3.03% | 0.86% | -8.16% | -37.9% |
| Price to Book | 21.2 x | 1.58 x | 1.6 x | 2.09 x | 1.1 x | 0.46 x |
| Nbr of stocks (in thousands) | 18,548 | 24,382 | 26,942 | 44,994 | 45,573 | 45,573 |
| Reference price 2 | 22.51 | 16.57 | 16.35 | 20.72 | 12.08 | 4.631 |
| Announcement Date | 4/1/19 | 4/30/20 | 3/31/21 | 4/5/22 | 3/31/23 | 5/1/24 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | 8.926 | 65.04 | 219.7 | 388.7 | 355.6 |
| EBITDA 1 | -10.12 | -79.4 | 1.425 | 35.53 | 48.34 | -27.74 |
| EBIT 1 | -10.13 | -79.98 | -1.205 | 30.41 | 40.85 | -40.9 |
| Operating Margin | - | -896.06% | -1.85% | 13.84% | 10.51% | -11.5% |
| Earnings before Tax (EBT) 1 | -12.8 | -3.669 | -38.31 | 18.74 | 43.84 | -61.28 |
| Net income 1 | -12.8 | -2.996 | -37.23 | 4.692 | 44.82 | -61.96 |
| Net margin | - | -33.56% | -57.25% | 2.14% | 11.53% | -17.43% |
| EPS 2 | -0.7125 | -0.1335 | -1.466 | 0.1000 | 0.9882 | -1.360 |
| Free Cash Flow 1 | 2.649 | -21.4 | -12.36 | 7.275 | -46.73 | -113.9 |
| FCF margin | - | -239.8% | -19% | 3.31% | -12.02% | -32.03% |
| FCF Conversion (EBITDA) | - | - | - | 20.48% | - | - |
| FCF Conversion (Net income) | - | - | - | 155.04% | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/1/19 | 4/30/20 | 3/31/21 | 4/5/22 | 3/31/23 | 5/1/24 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 19.89 | 26.39 | 25.71 | 29.28 | 29.5 | 29.42 | 28.99 | 26.94 |
| EBITDA 1 | - | 7.197 | 6.278 | 6.796 | 5.764 | 5.161 | - | 2.988 |
| EBIT 1 | 2.308 | 2.831 | 4.924 | 4.835 | 4.12 | 2.271 | 1.841 | 1.321 |
| Operating Margin | 11.6% | 10.73% | 19.15% | 16.51% | 13.96% | 7.72% | 6.35% | 4.9% |
| Earnings before Tax (EBT) 1 | 0.6695 | 0.7974 | 5.72 | 6.475 | 3.504 | -2.43 | 0.4844 | 0.106 |
| Net income 1 | -0.53 | -0.9567 | 3.942 | 4.689 | 2.128 | 2.382 | 0.0584 | 1.284 |
| Net margin | -2.66% | -3.63% | 15.33% | 16.01% | 7.21% | 8.1% | 0.2% | 4.77% |
| EPS | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 4/4/22 | 5/16/22 | 8/15/22 | 11/15/22 | 3/31/23 | 5/15/23 | 8/31/23 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 9.12 | - | - | - | 22.4 | 89.7 |
| Net Cash position 1 | - | 10.5 | 32.9 | 87.6 | - | - |
| Leverage (Debt/EBITDA) | -0.9003 x | - | - | - | 0.4627 x | -3.234 x |
| Free Cash Flow 1 | 2.65 | -21.4 | -12.4 | 7.27 | -46.7 | -114 |
| ROE (net income / shareholders' equity) | -61.9% | -2.17% | -13.1% | 1.94% | 8.83% | -13% |
| ROA (Net income/ Total Assets) | -20.7% | -31.4% | -0.25% | 3.75% | 3.09% | -2.93% |
| Assets 1 | 61.7 | 9.534 | 15,043 | 125 | 1,452 | 2,114 |
| Book Value Per Share 2 | 1.060 | 10.50 | 10.20 | 9.930 | 11.00 | 10.20 |
| Cash Flow per Share 2 | 0.1800 | 1.120 | 1.410 | 4.350 | 5.100 | 2.260 |
| Capex 1 | 0.09 | 28.1 | 20.8 | 14 | 19.7 | 2.62 |
| Capex / Sales | - | 315.3% | 32.05% | 6.39% | 5.08% | 0.74% |
| Announcement Date | 4/1/19 | 4/30/20 | 3/31/21 | 4/5/22 | 3/31/23 | 5/1/24 |
1ILS in Million2ILS
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +173.38% | 148M | |
| +47.33% | 289M | |
| +31.96% | 270M | |
| +50.00% | 193M | |
| -14.29% | 145M | |
| +52.39% | 143M | |
| -30.70% | 142M | |
| 0.00% | 80.17M | |
| +150.00% | 75.33M | |
| +52.81% | 66.15M |
- Stock Market
- Equities
- INCR Stock
- Financials InterCure Ltd.